Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

Cannabis interacts with our body’s endocannabinoid system, influencing mood, memory, and pain perception. While it offers ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development ...

Learn all about THCP’s effects and benefits and where to buy this naturally occurring cannabinoid, which is more potent than ...

THC binds to the CB1 receptor, found in the brain, but also in the myocardium, vascular endothelial, and smooth muscle cells. The CB1 receptor promotes atherosclerotic changes, Chandy explained ...

EU-funded researchers are working to reduce the health risks associated with Down syndrome and improve long-term quality of ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

This receptor is prone to excessive activity in those with Down syndrome, which is believed to contribute to cognitive impairments. AEF0217 acts as a selective CB1 inhibitor, reducing this ...

The acquisition will add SKNY-1 to Mira’s pipeline. Mira said the oral candidate is “designed to interact with cannabinoid receptors CB1 and CB2 pathways.” Interest in treating smoking and ...

IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...